COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

Rimesh Pal; Manoj K. Bhasin; Sanjay K. Bhadada

首页> 外文期刊>Infectious disorders drug targets >COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

【24h】

COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

机译：COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.

著录项

来源
《Infectious disorders drug targets》 |2021年第5期|3-6|共4页
作者
Rimesh Pal; Manoj K. Bhasin; Sanjay K. Bhadada;
展开▼
作者单位

Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh;

Department of Biomedical Informatics, Emory School of Medicine, Atlanta, GA-30322, United States;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
HCQ; diabetes mellitus; COVID-19; T2DM; vaccine; pandemic; SARS-CoV-2.;

COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail

摘要

著录项

相关主题

期刊订阅